FAT1 and acute myeloid leukemia: Therefore, in this study, we analyzed the characteristics, clinical features, and molecular genetic features of FAT1 mutations in AML and investigated the impact of FAT1 mutations on the therapeutic outcomes and prognosis of AML patients, particularly those receiving venetoclax combination therapy.